Sun Pharmaceutical Industries, Inc.

sunpharma.com

Total trials

79

Active

4

Phase 3

15

Total enrollment

40,476

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 3 of 3 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%2
CTP-5432
Deuruxolitinib1

Next readouts

  • 2027-01
  • 2027-01
  • 2027-05
  • 2028-05

Top conditions

  • Acne Vulgaris22
  • Plaque Psoriasis8
  • Tinea Pedis7
  • Psoriasis5
  • Actinic Keratosis5
  • Pediculosis4
  • Scalp Psoriasis4
  • Atopic Dermatitis4

Frequently asked questions about Sun Pharmaceutical Industries, Inc.

How many clinical trials does Sun Pharmaceutical Industries, Inc. have on ClinicalTrials.gov?
Sun Pharmaceutical Industries, Inc. is listed as the lead sponsor on 79 clinical trials in ClinicalTrials.gov, 4 of which are currently active (recruiting, enrolling, or ongoing).
How many of Sun Pharmaceutical Industries, Inc.'s trials are in Phase 3?
15 of Sun Pharmaceutical Industries, Inc.'s trials are in Phase 3, spread across 3 active drug programs.
What therapeutic areas does Sun Pharmaceutical Industries, Inc. focus on?
Sun Pharmaceutical Industries, Inc.'s most-studied conditions on ClinicalTrials.gov are Acne Vulgaris, Plaque Psoriasis, Tinea Pedis, Psoriasis, Actinic Keratosis.
When are Sun Pharmaceutical Industries, Inc.'s next clinical trial readouts?
Sun Pharmaceutical Industries, Inc. has 4 upcoming primary-completion readouts tracked here; the soonest is “Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities”, expected around 2027-01.